Author | Tomasz M. Beer, MD


Building on Last Year’s Advances

July 15, 2015

ByTomasz M. Beer, MD

The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

June 15, 2015

ByJulie N. Graff, MD|Tomasz M. Beer, MD

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Targeted Therapy in Prostate Cancer: Is There Hope Beyond the Androgen Receptor?

July 15, 2013

ByJoshi J. Alumkal, MD|Julie N. Graff, MD|Tomasz M. Beer, MD

We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time-for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

April 27, 2012

ByAndrew J. Armstrong, MD, MSc|Tomasz M. Beer, MD

Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.